Ikarian Capital’s Capricor Therapeutics CAPR Stock Holding History

Ikarian Capital’s Portfolio CAPR Stock Details CAPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.43M	Hold	350,000	–	–	0.91%	32
2026 Q1	$10.6M	Buy	+350,000	New	+$9.33M	0.86%	32
2025 Q4	–	Sell	-100,000	Closed	-$721K	–	187
2025 Q3	$721K	Sell	100,000 -600,000	-86%	-$4.42M	0.07%	129
2025 Q2	$6.95M	Buy	700,000 +300,000	+75%	+$3.17M	1.34%	27
2025 Q1	$3.8M	Buy	400,000 +38,900	+11%	+$540K	0.47%	44
2024 Q4	$4.98M	Buy	361,100 +61,100	+20%	+$1.07M	0.68%	41
2024 Q3	$4.56M	Buy	+300,000	New	+$1.48M	0.64%	45

Other funds holding CAPR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Ikarian Capital's CAPR Position: Q2 2026 in Review

Ikarian Capital increased its Capricor Therapeutics (CAPR) stake by 14% in Q2 2026, buying an estimated $2.31M and bringing the position to 604,215 shares worth $14.5M. The position accounts for 1.57% of the portfolio, ranked #16.

Ikarian Capital first reported a position in CAPR in Q3 2024 and has held it in 5 quarters since. The position peaked at $16.7M in Q4 2025. 170 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

Ikarian Capital held 604,215 shares of Capricor Therapeutics worth $14.5M as of Q2 2026.
Ikarian Capital bought 76,200 Capricor Therapeutics shares in Q2 2026, an estimated $2.31M.
Capricor Therapeutics made up 1.57% of Ikarian Capital's portfolio in Q2 2026, its #16 holding.
Ikarian Capital first reported a position in Capricor Therapeutics in Q3 2024 and has held it in 5 quarters since.
Ikarian Capital's Capricor Therapeutics position peaked at $16.7M in Q4 2025.
170 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.